The Neuromuscular Research Lab (NMRL) has participated in clinical trials targeting Duchenne Muscular Dystrophy (DMD) for over a decade. DMD is a rare X-linked neuromuscular genetic disorder that primarily affects boys. The disease typically presents by age two with delays in motor milestone achievements. It is characterized by irreversible muscle denegation and replacement of muscle tissue with fibro-fatty deposits. This genetic disorder has the lack of dystrophin, which is essential for muscle development and growth. Due to DMD’s progressive nature, early diagnosis and treatment is favorable as symptoms cannot be reversed. Since 2020, the NMRL has been involved in DMD gene therapy clinical trials and commercially approved gene therapies to deliver micro-dystrophin to improve muscle integrity and function. These gene therapies utilize a proprietary, rationally designed muscle-tropic recombinant adeno-associated virus (AAV) to deliver a functional micro-dystrophin to improve muscle integrity and function. The integration of these gene therapies has highlighted the importance of close coordination across multiple departments at UC Davis Health to bring the best care to each patient who is treated. There is collaboration between 1) Physical Medicine and Rehabilitation (NMRL), with 2) Investigational Drug Services, 3) Pediatric Hospitalists, 4) Cardiology, 5) Radiology, 6) Orthopedics, 7) Endocrinology, 8) Children’s Surgery Center, 9) Anesthesiology, 10) Pediatric Oncology Center, 11) Pathology, 12) PACU, 13) Pediatric Hematology & Oncology, 14) Pre-Operation. The interdisciplinary care model spans both inpatient and outpatient services, underscoring the critical role of cross-specialty collaboration in delivering advanced therapies like gene therapy. The comprehensive and patient-centered approach by the NMRL is what makes gene therapy treatment feasible and well-received, which leads to families preferring to continue their care journey at UC Davis Health